Article: Kunming Pharmaceutical launches artemisinin project.(NEWSDESK: Expansion)

Kunming Pharmaceutical Corp. (SH: 600422) announced on February 27th that the Board of Directors of the company had decided to launch an artemisinin compound antiperiodic ARCO project.

The 4 100 [m.sup.2] project mainly produces ARCO and the design capacity is I00 million pcs/a tablets and 50 million pcs/ a capsules. The construction period is one year. The total investment is RMB49.89 million including RMB39.89 million to be raised by the company itself and RMB10.0 million to be supported by ...

Related newspaper, magazine, and journal articles:

 
 
Newsweek Harper's Magazine The Washington Post Chicago Tribune Crain's Chicago Business PRNewswire Pediatric News The Nation Advertising Age The Economist (US) A FREE trial gives you access to over 80 million articles! Access over 6,500 publications with a FREE trial!